Amgen’s trial drug to fight autoimmune disorder improves patient outcomes
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.